SCHEMBL2036023

SCHEMBL2036023

CCOP(C)(=O)Cc1ccc(N)c(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
HDAC1 Q13547 1/20 0.43
CYP3A4 P08684 2/20 0.42
HSD17B10 Q99714 2/20 0.42
TSHR P16473 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HTT P42858 2/20 0.40
GAA P10253 1/20 0.39
CYP19A1 P11511 2/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
MET P08581 3/20 0.36
APP P05067 1/20 0.36
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2034890 0.88 ALDH1A1 (0.54) ALDH1A1HDAC1CYP3A4HSD17B10TSHR
SCHEMBL2029808 0.87 ALDH1A1 (0.56) ALDH1A1HDAC1CYP3A4HSD17B10TSHR
SCHEMBL2637408 0.80 ALDH1A1 (0.59) ALDH1A1CYP3A4HSD17B10TSHRTDP1
SCHEMBL2029517 0.79 ALDH1A1 (0.54) ALDH1A1CYP3A4HSD17B10TSHRTDP1
SCHEMBL2636910 0.78 ALDH1A1 (0.61) ALDH1A1CYP3A4HSD17B10TSHRTDP1
SCHEMBL25612375 0.78 PPARG (0.41) ALDH1A1HDAC1HSD17B10TSHRTDP1
SCHEMBL2031264 0.78 ALDH1A1 (0.42) ALDH1A1CYP3A4TDP1HTTGAA
SCHEMBL9277017 0.76 ALDH1A1 (0.50) ALDH1A1HDAC1CYP3A4HSD17B10TSHR
SCHEMBL2029488 0.76 HDAC1 (0.43) ALDH1A1HDAC1CYP3A4TSHRTDP1
SCHEMBL9275716 0.75 ALDH1A1 (0.53) ALDH1A1CYP3A4HSD17B10TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399433-B2 Amino pyrimidine anticancer compounds OSI Pharmaceuticals, LLC (US) 2013-03-19 US disclosed
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2011-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136764-A1 AMINO PYRIMIDINE ANTICANCER COMPOUNDS DPYD, PTK2, TYMS ALDH1A1 1117/4885HDAC1 1897/4885CYP3A4 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.